Novo Nordisk says receives subpoena in the U.S.
COPENHAGEN (Reuters) - Denmark's Novo Nordisk said on Wednesday it had received a subpoena in the United States regarding potential criminal offences relating to marketing and promotion practices for a number of its products.
The world's biggest maker of insulin said in a statement that the office of the United States attorney for the District of Massachusetts had asked for documents relating to Novo Nordisk's diabetes products Novolog, Levemir and Victoza.
Novo said it would cooperate with the attorney in the investigation, and that the group was at this point unable to determine or predict the outcome of the matter, or assess the consequences.
It was not possible to predict how long the investigation would take, Novo Nordisk said in the statement.
- Investigators look for motive in Malaysia plane disappearance |
- Malaysian PM says lost airliner was diverted deliberately |
- Democrats seek ways to limit Obamacare fallout after Florida defeat
- Police make third arrest in murder of Colorado socialite
- Exclusive: Radar data suggests missing Malaysia plane deliberately flown way off course - sources